adamantylidene has been researched along with Chagas Disease in 1 studies
*Chagas Disease: Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrias, E; Calogeropoulou, T; de Souza, W; Reignault, LC | 1 |
1 other study(ies) available for adamantylidene and Chagas Disease
| Article | Year |
|---|---|
In vitro activities of adamantylidene-substituted alkylphosphocholine TCAN26 against Trypanosoma cruzi: Antiproliferative and ultrastructural effects.
Topics: Adamantane; Animals; Antiprotozoal Agents; Autophagy; Cell Membrane; Chagas Disease; Dose-Response Relationship, Drug; Flow Cytometry; Golgi Apparatus; Inhibitory Concentration 50; Lethal Dose 50; Macrophages, Peritoneal; Mice; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Microscopy, Immunoelectron; Mitochondria; Phosphorylcholine; Trypanocidal Agents; Trypanosoma cruzi | 2019 |